Parkin and mitophagy in cancer
Details
Publication Year 2017, Volume 36, Issue #10, Page 1315-1327
Journal Title
Oncogene
Publication Type
Journal Article
Abstract
Mitophagy, the selective engulfment and clearance of mitochondria, is essential for the homeostasis of a healthy network of functioning mitochondria and prevents excessive production of cytotoxic reactive oxygen species from damaged mitochondria. The mitochondrially targeted PTEN-induced kinase-1 (PINK1) and the E3 ubiquitin ligase Parkin are well-established synergistic mediators of the mitophagy of dysfunctional mitochondria. This pathway relies on the ubiquitination of a number of mitochondrial outer membrane substrates and subsequent docking of autophagy receptor proteins to selectively clear mitochondria. There are also alternate Parkin-independent mitophagy pathways mediated by BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 and Nip-3 like protein X as well as other effectors. There is increasing evidence that ablation of mitophagy accelerates a number of pathologies. Familial Parkinsonism is associated with loss-of-function mutations in PINK1 and Parkin. A growing number of studies have observed a correlation between impaired Parkin activity and enhanced cancer development, leading to the emerging concept that Parkin activity, or mitophagy in general, is a tumour suppression mechanism. This review examines the molecular mechanisms of mitophagy and highlights the potential links between Parkin and the hallmarks of cancer that may influence tumour development and progression.Oncogene advance online publication, 5 September 2016; doi:10.1038/onc.2016.302.
Publisher
SPRINGER NATURE
WEHI Research Division(s)
Cell Signalling And Cell Death
PubMed ID
27593930
ARC Grants
ARC/FT100100791,
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2016-10-03 03:38:06
Last Modified: 2018-07-11 09:18:16
An error has occurred. This application may no longer respond until reloaded. Reload 🗙